[Apixaban in the treatment of venous thrombosis associated with permanent pacemaker implantation]

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Venous thromboembolism (VTE) is a significant cause of vascular disease morbidity and mortality.
• Newer oral anticoagulants (NOACs) are emerging as effective and safe alternatives to traditional antithrombotic treatments.
• Apixaban is a recently approved NOAC for treating deep vein thrombosis.

Observation:

• An elderly patient presented with superficial venous thrombosis in the arm ipsilateral to a recent pacemaker implant.
• The patient had a high risk of bleeding and a history of cancer.

Findings:

• The patient was successfully treated with apixaban.
• Apixaban demonstrated efficacy in managing superficial venous thrombosis in a complex patient profile.

Implications:

• This case highlights the potential utility of apixaban in managing venous thromboembolism, even in high-risk patients.
• Apixaban may be a viable therapeutic option for superficial venous thrombosis, offering a favorable safety profile.
• Further research into apixaban's role in diverse VTE presentations is warranted.